Trevi Therapeutics (TRVI) Operating Expenses (2018 - 2025)
Trevi Therapeutics (TRVI) posted quarterly Operating Expenses of $10.2 million for Q4 2025, down 16.52% year-over-year from $12.2 million in Q4 2024, and down 26.56% quarter-over-quarter from $13.9 million in Q3 2025.
Trevi Therapeutics (TRVI) Operating Expenses (2018 - 2025) Analysis & Trends
Trevi Therapeutics' Operating Expenses history runs 8 years deep, the most recent figure standing at $10.2 million for Q4 2025.
- In Q4 2025, Operating Expenses fell 16.52% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $37.9 million (down 4.44% YoY), while the FY2025 annual figure was $49.3 million, down 4.26% from the prior year.
- Operating Expenses for Q4 2025 stood at $10.2 million, down from $13.9 million in the prior quarter.
- The five-year high for Operating Expenses was $14.1 million in Q3 2024, with the low at $6.7 million in Q4 2022.
- The 5-year median for Operating Expenses is $8.9 million (2023), against an average of $9.8 million.
- The sharpest annual moves came in 2022 and 2024: Operating Expenses retreated 19.53% in 2022, then soared 58.54% in 2024.
- Trevi Therapeutics' Operating Expenses stood at $8.3 million in 2021, then decreased by 19.53% to $6.7 million in 2022, then surged by 34.19% to $8.9 million in 2023, then surged by 37.05% to $12.2 million in 2024, then decreased by 16.52% to $10.2 million in 2025.
- Business Quant data shows TRVI's Operating Expenses at $10.2 million in Q4 2025, $13.9 million in Q3 2025, and $13.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.22 Mn |
| Sep 30, 2025 | 13.92 Mn |
| Jun 30, 2025 | 13.72 Mn |
| Dec 31, 2024 | 12.24 Mn |
| Sep 30, 2024 | 14.09 Mn |
| Jun 30, 2024 | 13.29 Mn |
| Mar 31, 2024 | 11.91 Mn |
| Dec 31, 2023 | 8.93 Mn |
| Sep 30, 2023 | 9.05 Mn |
| Jun 30, 2023 | 8.38 Mn |
| Mar 31, 2023 | 7.56 Mn |
| Dec 31, 2022 | 6.66 Mn |
| Sep 30, 2022 | 8.41 Mn |
| Jun 30, 2022 | 7.82 Mn |
| Mar 31, 2022 | 7.03 Mn |
| Dec 31, 2021 | 8.27 Mn |
| Sep 30, 2021 | 6.95 Mn |
| Jun 30, 2021 | 9.17 Mn |
| Mar 31, 2021 | 8.09 Mn |
| Dec 31, 2020 | 9.19 Mn |